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 The great burden that noncommunicable diseases (NCDs) and injuries have on low-
income and middle-income countries is 
well recognized [1,2]. Latin American 
and Caribbean (LAC) countries as 
a group of middle-income countries 
are no exception to this neglected 
epidemic. In this Essay, we review the 
impact on public health of NCDs and 
injuries in LAC countries, as well as 
describe the regional particularities 
behind this epidemic. We discuss the 
reasons why LAC countries are in a 
privileged position to quickly translate 
investment in health research into 
practice. Finally, we describe possible 
research needs and the implications of 
this research for clinical practice and 
health policy in the region. 
 Epidemiological Proﬁ le of LAC 
Countries 
 LAC countries, with a combined 
population of about 533 million 
people, have been experiencing in 
the last decades a rapid, complex 
epidemiological transition. By 1990, 
NCDs and injuries had already 
accounted for 69% of deaths and 
65% of disability-adjusted life years 
(DALYs), a pattern still evident in 2000 
(73% of deaths and 76% of DALYs). 
The largest impact on mortality was a 
result of cardiovascular disease, while 
for DALYs the greatest proportion was 
due to two neglected health problems: 
mental illness and injuries (Figures 1 
and 2) [3]. This dominance of NCDs 
and injuries over infectious disease is 
expected to rise signiﬁ cantly by 2020, 
when the ratio of deaths from NCDs 
and injuries to deaths from infectious 
disease might increase from 2.2 to 8.1; 
likewise, a similar increase is expected 
to occur with the ratio of DALYs, 
increasing from 1.8 to 6.9 [3]. 
 The Epidemic of NCDs and Injuries 
in LAC Countries
 In addition to urbanization, the 
two major driving forces of this 
epidemiological transition are 
globalization and the aging of the 
population. Life expectancy in LAC 
countries increased from 63.4 years in 
the period 1975–1980 to 72.2 in the 
period 2000–2005, and the population 
aged 65 years and older is expected 
to almost double, from 5.5% in 2000 
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 Figure 1.  Distribution of Total Deaths (3,537,000) by Major Causes in LAC Countries in 2000, 
Estimated by the Global Burden of Disease Study
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to 9.8% in 2025 [4]. Globalization, 
including the globalization of the mass 
media, has contributed to an increase 
in unhealthy lifestyles in LAC countries, 
such as worsening dietary patterns 
and lower levels of physical activity. 
These changes in lifestyle have in turn 
contributed to the epidemic of NCDs 
and injuries [5]. In addition, there are 
a number of features that are particular 
to the region that have also played a 
role in the rise in NCDs and injuries. 
 Social Inequality 
 The LAC region has the highest level 
of social inequality of any region in 
the world. In 1990 the wealthiest 
20% of the LAC population earned 
52.4% of the area’s income, while the 
poorest 20% earned only 4.5% [6]. 
This inequality is not only greater than 
that in developed countries but also 
greater than the inequality observed 
in other developing countries, as 
evaluated by the GINI coefﬁ cient—a 
measure of income inequality. In 1990 
the GINI coefﬁ cient was 0.51 for LAC 
countries, a value higher than that for 
Africa (0.46), the Middle East (0.38), 
Southeast Asia, (0.37), or Eastern 
Europe (0.29) [6,7]. 
 Social inequality is reﬂ ected in 
inequities in access to health care. The 
poor have worse access to care, which 
means they have less opportunity to 
receive treatment to control risk factors 
for chronic disease (e.g., high blood 
pressure) and to manage established 
chronic diseases and injuries [8]. 
And, as in developed countries, 
social inequalities are also reﬂ ected 
in differences in health status and 
risk factors independent of access to 
health care [9,10]. In Peru, a recent 
study showed that individuals with the 
lowest socioeconomic status had a 4-
fold increased risk of having multiple 
cardiovascular risk factors compared to 
those with the highest socioeconomic 
status [9]. 
 Another important and often 
neglected effect of social inequality 
is its impact on mental health and 
injuries in the young. Individuals from 
deprived areas, with lower educational 
levels, have the highest prevalence of 
mental health problems, as recently 
described in Colombia [11]. The LAC 
region has one of the world’s highest 
rates of intentional injuries (including 
homicide)—more than twice the world 
average—affecting disproportionably 
young men from disadvantaged social 
groups [3,12]. The LAC region also has 
a high rate of unintentional injuries, 
such as road trafﬁ c crashes, which are 
strongly and positively associated with 
poverty levels and lower literacy rates 
[13]. 
 In addition to the effects of social 
inequalities on the epidemic of 
NCDs and injuries, the epidemic also 
contributes to the impoverishment 
of families and places an economic 
burden on the already-limited health-
care budgets of LAC countries. This 
economic burden is accounted for not 
only by the high incidence of NCDs 
and injuries, but also by the high 
probability of developing disease at 
younger ages and often presenting with 
a poorer prognosis [14].
 Urbanization and forced rural–urban 
migration. In the LAC region, the 
proportion of urban population 
increased from 56.5% in 1970 to 
almost 78% in 2005 [4]. Associated 
with this unplanned urbanization 
in LAC countries is the growth of 
poor, peripheral urban settlements 
and a rapid rise in the number of 
middle-sized cites, added to the 
already-existing “mega-cities” of Latin 
America [15]. Furthermore, in the last 
two decades in some LAC countries, 
this urbanization has been fueled 
by a second wave of rural–urban 
migration—usually as a consequence of 
internal civil violence.
 In Colombia, it is estimated that 
in the last 15 years around 2 million 
people (4.3% of the total population) 
have been forcibly displaced from their 
rural communities as a result of armed 
conﬂ ict [16]. Importantly, the low 
educational and socioeconomic level 
of this new wave of forced migrants has 
led them to settle in the existing poor, 
peripheral urban areas [16]. A similar 
scenario has occurred over the past 20 
years in Peru, where the population 
of Lima increased from 3.5 million 
people in 1972 to 8 million in 2002—a 
phenomenon that was mainly caused by 
social violence [17]. Although there is 
no clear evidence of the consequences 
of this forced migration on NCDs and 
injuries, it is likely that this migration 
further increases the existing social 
inequalities. In turn, worsening 
inequalities affect individual and public 
health. 
 Lack of adequate local and regional 
funds. In 2003 funds allocated to 
research and development (R&D) in 
the LAC region accounted for only 
0.57% of the gross domestic product 
(http://www.ricyt.edu.ar), which lags 
behind other countries such as the 
United Kingdom (1.9%) or the United 
DOI: 10.1371/journal.pmed.0030344.g002
 Figure 2.  Distribution of Total DALYs (102,108,000) by Major Causes in LAC Countries in the 
Year 2000, Estimated by the Global Burden of Disease Study
 Latin American and Caribbean countries included are listed in Figure 1. 
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States (2.58%) (Chapter 4 of [18]). 
These scarce funds for R&D are also 
reﬂ ected in the poor output of research 
publications. In 1996, for example, 
only 2.1 Latin American articles were 
registered by the Institute for Scientiﬁ c 
Information for each million dollars 
allocated for R&D; in Spain, this same 
quantity of resources generated four 
Institute for Scientiﬁ c Information-
registered articles [19]. 
 Moreover, the limited funds for 
R&D in the LAC region are not usually 
allocated in proportion to the current 
burden of disease. A review of scientiﬁ c 
production, an accepted proxy of 
research conducted, showed that in the 
LAC region a large majority (83%) of 
epidemiological publications focused 
on infectious diseases [20]. 
 Translating Investment in Health 
Research into Practice
 In the LAC region, rapid translation 
of research investment into improved 
public health is highly feasible 
[21]. As a group of middle-income 
countries, the LAC countries have an 
adequate technology-communications 
infrastructure, as well as highly 
qualiﬁ ed health and academic human 
resources—essential for conducting 
high-quality human epidemiological 
research. Furthermore, LAC countries 
share a similar cultural identity, 
and most of the population shares a 
common language, which undoubtedly 
would strengthen regional initiatives 
in collaborative research. These 
favorable advantages, added to the 
low cost of conducting research in 
the region compared with the costs 
in developed countries, have been 
used by pharmaceutical companies to 
actively recruit LAC populations into 
randomized clinical trials. The number 
of US-based trials executed in LAC 
countries has increased over 10-fold 
from 1995 to 2000, making the LAC 
countries the fourth-largest clinical 
trial market [22]. Unfortunately, these 
clinical trials often do not address 
diseases with a great burden to the 
region (e.g., mental health, chronic 
respiratory disease, and trauma). 
In addition, trials conducted in the 
LAC population, while sometimes 
addressing relevant pathologies such 
as cardiovascular disease, usually 
involve interventions that would not 
be affordable to LAC populations or 
that would be difﬁ cult to implement 
in settings with inadequate health-
care resources [22]. Nevertheless, in 
recent years examples of relevant trials 
conducted in LAC countries using 
affordable interventions are emerging, 
such as the CRASH, DIAL, and 
BENEFIT trials (Box 1) [23–25]. There 
are also examples of observational 
epidemiology evaluating questions 
relevant to the LAC region, such as the 
PLATINO [26] and INTERHEART 
[27] studies (Box 1). 
 Why LAC Countries Need More 
Research on NCDs and Injuries
 Some would argue that there is no 
need for regional research since 
studies conducted anywhere in the 
world should be applicable to different 
settings. Although we consider that 
most of the biological determinants of 
NCDs and injuries in LAC are likely 
to be similar to those in other parts of 
the world, the population-attributable 
risk and the circumstances in which 
those disease determinants arise and 
progress are indeed different between 
populations. Understanding the impact 
of rural–urban migration (unforced 
and forced) and urbanization on risk 
factors for NCDs and injuries is crucial. 
The effects of the existing, large social 
inequalities on the development and 
progression of NCDs and injuries and 
their risk factors may differ within and 
between LAC countries, and these 
effects may be different within the LAC 
region compared with the rest of the 
world [28]. 
 Evidence derived from studies 
conducted in developed countries 
has suggested that the rise in chronic 
diseases is largely explained by a few 
modiﬁ able risk factors (smoking, 
blood pressure, cholesterol, and 
obesity), and that interventions aimed 
at producing small changes in those 
risk factors at population level are 
highly cost-effective [1]. However, the 
development and implementation of 
such policies in developing countries is 
a complex challenge. 
 Regional research is therefore 
of great importance since some 
interventions, such as changing 
behavior, for preventing NCDs and 
injuries with long, complex pathways 
could be effective in one setting 
but ineffective in a resource-poor 
context—a phenomenon known as 
“transferability” of evidence [29]. For 
example, a systematic review of street 
lighting showed a protective effect on 
road trafﬁ c crashes, but all of the data 
came from developed countries [30]. 
To assume that this intervention would 
be just as effective in LAC countries is 
inappropriate because of behavioral, 
 Box 1. Studies Relevant to LAC 
Countries 
 Trials conducted in LAC countries 
using affordable interventions:
 •  BENEFIT trial: “The purpose of this 
study is to determine if 60 days 
of treatment with an antiparasitic 
drug (benznidazole) could prevent 
the progression of cardiac disease 
in patients with Chagas disease” 
(http://clinicaltrials.gov/ct/show/
NCT00123916).
 •  CRASH trial: “A large simple, placebo 
controlled trial of the effects of a 48-
hour infusion of corticosteroids on 
death and on neurological disability, 
among adults with head injury and 
some impairment of consciousness” 
(http://www.crash.lshtm.ac.uk/
TP_English_StudyDesgn.htm).
 •  DIAL trial: A randomized trial “to 
see whether a program based on 
centralized telephone intervention 
performed by trained nurses can 
reduce the high rates of morbidity 
and mortality associated with chronic 
heart failure compared with ‘usual 
care’ administered by an attending 
cardiologist” (http://www.medscape.
com/viewarticle/444970).
 Observational studies evaluating 
questions relevant to LAC countries:
 •  INTERHEART study: “The aim of 
INTERHEART, a case-control study 
conducted in > 50 countries, was to 
determine the associations between 
a wide array of risk factors and AMI 
[acute myocardial infarction] within 
populations deﬁ ned by ethnicity and/
or geographic region, and to assess the 
relative importance of these risk factors 
across these populations” (http://www.
medscape.com/viewarticle/489738).
 •  PLATINO study: The aim of this study, 
launched in 2002, “was to describe 
the epidemiology of COPD [chronic 
obstructive pulmonary disease] in ﬁ ve 
major Latin American cities: São Paulo 
(Brazil), Santiago (Chile), Mexico City 
(Mexico), Montevideo (Uruguay), and 
Caracas (Venezuela)” [26]. 
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vehicular, and environmental 
differences [30]. 
 In addition, some health problems 
are of greater relevance to LAC 
countries (e.g., cardiomiopathy due 
to Chagas disease and road trafﬁ c 
injuries) than to developed countries, 
and randomized evidence to support 
effective interventions to address these 
problems is urgently needed [31,32]. 
Finally, as previously mentioned, 
many treatments that are affordable 
in developed countries are beyond the 
reach of a large proportion of the LAC 
population.
 There is one additional beneﬁ t that 
would be associated with a growth in 
regional research in LAC countries. If 
more health practitioners were to get 
involved in such research, they would 
become familiar with the principles 
of research methodology, and this in 
turn may stimulate their practice of 
evidence-based medicine. Greater use 
of the best-available evidence may be 
beneﬁ cial to population health. 
 Although we believe that the global 
burden of disease should be used to 
guide research priorities in the LAC 
region, we acknowledge that there 
are additional considerations. First, 
different LAC countries are at different 
stages of the epidemiological transition, 
and so each country needs its own 
speciﬁ c research agenda. Second, this 
agenda should also consider issues such 
as addressing health inequality and 
improving health-care services. Third, 
the process of establishing the research 
agenda must include all the relevant 
sectors of the society (government, the 
public, academia, nongovernmental 
organizations, and the private sector) 
[33,34].  
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